Rnai therapeutic for respiratory virus infection

A respiratory and viral technology, applied in respiratory diseases, DNA/RNA fragments, antiviral agents, etc., can solve the problems of antigenic drift, limited vaccine potency, and no better treatment plan for influenza virus infection

Inactive Publication Date: 2008-05-21
NASTECH PHARMA
View PDF17 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no good treatment option for influenza virus infection, and the potency of existing va

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rnai therapeutic for respiratory virus infection
  • Rnai therapeutic for respiratory virus infection
  • Rnai therapeutic for respiratory virus infection

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0141] siRNA preparation

[0142] In one embodiment, siRNA is synthesized in vivo or in vitro. The cell's endogenous RNA polymerase can mediate in vivo transcription, or the cloned RNA polymerase can be used for in vivo or in vitro transcription. For transcription from transgenes or expression constructs in vivo, regulatory regions (such as promoters, enhancers, silencers, or splice donors and acceptors) can be used to transcribe siRNA. Through specific transcription in organs, tissues, or cell types; stimulation by environmental conditions (such as infection, stress, temperature, ski inducer); and / or engineered transcription at the developmental stage or age can be targeted for inhibition. By introducing recombinant constructs into fertilized eggs, embryonic stem cells, or other pluripotent cells from suitable organisms, transgenic organisms expressing siRNA from the recombinant constructs can be produced.

[0143] In addition, not only siRNA can be used to produce multiple RNA...

Embodiment 1

[0198] Example 1: Identification of viral nucleoprotein

[0199] A highly conserved site is considered to be a site or sequence present in most available human influenza sequences. The variant is identified as a 19-mer sequence in a human influenza isolate, similar to the conservative 19-mer sequence, but with only one or a few nucleotide changes. This is important because using siRNA duplexes, RISC (RNA-induced silencing complex) can still initiate RNAi activity. The guide strand (antisense strand) of the siRNA duplex is largely complementary to the target mRNA sequence, but relative to Exact complementation has one or a few nucleotide changes.

[0200] There are eight different RNA segments that make up the influenza virus genome. All analyses are performed separately for each virus fragment. Therefore, for example, only the sequence obtained from the fragment #1 is used to study the conserved sites of the virus fragment #1.

[0201] Obtain the influenza A virus sequence of each...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Double-stranded siRNA molecules and uses thereof are disclosed herein, wherein each strand of the siRNA molecule is about 15 to about 50 nucleotides, and wherein one strand of the siRNA molecule includes a Nucleic acid sequences with identical conserved sites or variants in nucleic acid sequences.

Description

[0001] Sequence Listing [0002] The sequence table used in this application was submitted on a high-density disk instead of printed paper. The disk was recorded on September 1, 2006 and labeled CRF "Copyl", "Copy2" and "Copy3". Each disk contains only the name A 1.68 MB file of "0525PCT.APP", which is hereby incorporated by reference in its entirety. Invention field [0003] The present invention generally relates to the field of treatment and prevention of viral infections. The present invention also relates to the field of using RNA interference (RNAi), especially antiviral siRNA and shRNA. Background of the invention [0004] RNA interference (RNAi) is a gene regulation mechanism ubiquitous in plants and animals, in which target mRNA is degraded in a sequence-specific manner (Sharp, PA, Genes Dev. 15, 485-490 (2001); Hutvagner, G. & Zamore, PD, Cuur. Opin. Genet. Dev. 12, 225-232 (2002); Fire, A., etc., Nature 391, 806-811 (1998); Zamore, P., etc., Cell101, 25- 33(2000)). The ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/11C12N15/113
CPCC12N15/1131C12N2310/14C12N2310/321C12N2310/53C12N2310/111A61P11/00A61P31/12A61P31/14A61P31/16A61P37/04C12N2310/3521A61K48/00C12N7/00
Inventor 葛青缪克斯·库玛尔詹姆士·安东尼·麦克斯威根
Owner NASTECH PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap